With unintended weight loss, you can’t afford to wait

Manage unintended weight loss in cats with Mirataz® (mirtazapine transdermal ointment)

Scale icon.

In a clinical study, Mirataz resulted in significant weight gain in cats in as little as 14 days following topical application of 2 mg per day1

Ointment tube icon.

Mirataz gives you a practical way to manage your patient’s weight loss without administration of oral medication and does not rely on the cat to eat to be medicated

Health shield icon.

Mirataz was safe both locally and systemically in a clinical study1

Formulated using proprietary Accusorb technology, Mirataz achieves measurable plasma concentrations of mirtazapine in cats2

For More Information:

Contact your Dechra Representative or call (866) 683-0660.

To Place An Order Now:

Contact your Dechra or Distributor Representative or call (866) 683-0660.

Resources
Download Veterinary Detailer

Mirataz is indicated for the management of weight loss in cats.

Important Safety Information

Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.

References

1. Poole M, Quimby JM, Hu T, et al. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. J Vet Pharmacol Ther. 2019;42(2):179-188.

2. Buhles W, Quimby JM, Labelle D, et al. Single and multiple dose pharmacokinetics of a novel transdermal ointment in cats. J Vet Pharmacol Ther. 2018;41(5):644-651.

US Patent 10,603,272
Mirataz® is a registered trademark of Dechra Ltd.